Skip to main content
Premium Trial:

Request an Annual Quote

Definiens and BioImage Pen High-Content Screening Alliance

NEW YORK, Dec. 6 (GenomeWeb News) - Definiens and BioImage will co-market their products for high-content cell-based screening assays, and co-develop applications in this area, the companies said today.


Under the non-exclusive deal, the companies will co-market Definiens' Cellenger software for automated image analysis and BioImage's Redistribution cell-based pathway screenings assays, which measure protein translocation.


In addition, Definiens, based in Munich, Germany, and BioImage of Copenhagen, Denmark, plan to co-develop specific applications for high-content screening.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.